Modulators of cystic fibrosis transmembrane conductance regulator protein
US10118916B2 · kind B2 · utility
26Cited by
2References
50Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 25, 2017 |
| Grant date | Nov 6, 2018 |
| Priority date | — |
| Expiry date | Apr 25, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D407/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides for compounds of formula (I) wherein R1, m, Z, G1, R2, and R3 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.